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was conﬁgured and used clinically we checked that the number of patients who failed in the COVER step was in agreement with
the statistical simulations so that the proportion of protocol restarts was low.
Conclusions. The NAL+COVER setup protocol proved to be efﬁcient in the minimization of systematic errors in patient positioning,
keeping the additional workload at acceptable values and in good agreement with statistical simulations.
http://dx.doi.org/10.1016/j.rpor.2013.03.777
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Introduction. Total lymphoid irradiation (TLI) impairs the immunologic reaction to allergenic cells, and has been used successfully
to reduce the rate of decline of pulmonary function in patients with evolving or established Bronchiolitis obliterans syndrome
(BOS) despite treatment with immunosuppression regimen.
Objective. To present the single center experience to assess the safety and efﬁcacy of total lymphoid irradiation in controlling
progressive BOS.
Methods. We reviewed patients with BOS after lung transplantation that were treated with TLI at Vall d’Hebron Hospital from
May 2011 to February 2013. Eleven patients were treated with TLI upon treatment failure of drug-based immunosuppression.
Radiation therapy was prescribed as 8 Gy delivered in 10 fractions, 2 fractions/week, in a lineal accelerator with photons of
6–18MV. An AP-PA technique was used with table and collimator rotations to compensate divergencies. Results were assessed
by comparing the highest FEV1 obtained after transplantation and the corresponding BOS classiﬁcation with FEV1 at 3, 6 and 12
months after TLI.
Results. Were analyzed 7 women and 4 men, with a median age of 51.5 years (37–68). The average time between rejection and
TLI was 7.5 months (5–19). BOS classiﬁcation at that time was grade 1, 2 and 3 in 1, 7 and 3 patients respectively. One patient
did not complete the whole treatment due to worsening pulmonary infection. Two patients died, due to BOS progression and
pneumonia, 8 days and 5 months after TLI, respectively. The maximum toxicity reported was gastrointestinal grade 2, accounted
in two patients. The average decrease in FEV1 pre-TLI was 1110cc (580–2150). Pre TLI FEV1 decline was 64.4mls/month, and
27.3mls/month postTLI.
Conclusions. TLI signiﬁcantly reduces the decline rate of FEV1. In our experience, TLI demonstrated important decreased rejection
rates without relevant toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.778
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Introduction. Until 5 years ago, patients diagnosed with spinal chordoma were referred to protontherapy centers for treatment.
However, when newer, more advanced technologies became available at our centre, we began using photon-beam therapy to
treat these patients. The availability of high-dose conformal radiotherapy enabled us to manage these patients ourselves. The
present report describes our short term results with this technique.
Objective. To evaluate preliminary results in toxicity and local control in patients treated with photon-beam therapy for spinal
chordoma at our center.
Material. We report on 12 patients with histologically-proven lumbosacral chordoma treated at our center since 2008. The location
of the chordomas was as follows: sacral (7 cases), lumbar (4), and lumbosacral junction (1). All cases were primary except for
one case of multifocal relapse. Previous surgery was complete in 2 patients, subtotal in 4, and partial in 6. Intensity modulated
radiotherapy (IMRT) was used in 11 of the 12 cases (dynamic IMRT in 58% of cases and volumetric IMRT in 33%), with the
exception of one patient that was treated with conformal 3DRT. The mean dose to target volume (PTV1) was 70 Gy. Five patients
received a boost over high risk areas (PTV11), for total mean dose of 78 Gy. Overall survival and local control was obtained using
Kaplan-Meyer estimator.
Results. Treatment was well-tolerated by all patients, with only a single case of grade 3 acute dermatitis. Local control and long-
term toxicity were evaluated in the ﬁrst 9 patients, with a local control rate of 66.7% and overall survival of 100% at two years
after a median follow up of 21 months (range 3–44). Given the limited number of events, it was not possible to identify prognostic
factors. No severe chronic toxicity was observed.
